Here are three things to know.
1. Ixifi is a biosimilar version of Johnson & Johnson’s immunosuppressive drug Remicade.
2. The drug is intended to treat rheumatoid arthritis, Crohn’s disease and plaque psoriasis, among other illnesses.
3. Both Ixifi and Remicade contain a boxed warning over an increased risk of serious infections and cancer.
More articles on supply chain:
Eli Lilly forecasts $23B in revenue for 2018
Investor group pushes big pharma to report links between pricing and executive compensation
FDA to add alternative approval pathway for medical devices: 4 things to know
